New Provisional Patents Filed for Pharmaceutical Cannabidiol (CBD) Formulation Consisting of Ibuprofen & CBD Compounds Aimed At Treating Pain

CORAL SPRINGS, Florida, January 20, 2015 /PRNewswire/ --

Cannabinoids, including cannabidiol (CBD) are an essential part of hemp and cannabis medicine that consist of aromatic compounds that work in concert to promote healing and well being through the consistent symptom relief.  Leading Cannabidiol Development Solutions Providers in focus today are: Stevia Corp. (OTC: STEV), GW Pharmaceuticals plc  (NASDAQ: GWPH), INSYS Therapeutics, inc. (NASDAQ: INSY), CannaVEST Corp. (OTC: CANV) and American Green, Inc. (OTC: ERBB)

Stevia Corp. (OTCQB: STEV), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of a second important provisional patent application with the United States Patent and Trademark Office for the treatment of pain using ibuprofen and Cannabidiol (CBD).   The provisional patent application closely follows the company's previously announced first provisional patent application for pain comprising acetaminophen and CBD. As in the previously filed application, this patent includes multiple claims including but not limited to combinations of cannabinoids including CBD and ibuprofen for the treatment of pain. The provisional patent application was filed with the assistance of an intellectual property attorney with extensive experience in the healthcare industry. A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a patent with similar claims after the filing date of our provisional patent.

Read the full STEV press release at http://www.financialnewsmedia.com/profiles/stev.html

Ibuprofen is a non-steroidal drug that can be used to relieve pain and reduce fever. Ibuprofen is also widely recognized as a non-steroidal anti-inflammatory drug (NSAID). Like many NSAIDs, ibuprofen works by inhibiting the synthesis of prostaglandins which are fat-like molecules that are involved in mediating inflammation, pain and fever. It achieves this synthesis by inhibiting cyclooxygenase, an enzyme that is present in various tissues of the body. Ibuprofen is the active ingredient in popular OTC (over-the-counter) analgesics such as Advil® and Motrin®. For most pain sufferers, use of these drugs requires a long term, daily dosing regimen.

Cannabidiol (CBD) is a cannabinoid that is present in most varieties of the cannabis sativa and cannabis indica plants. Cannabinoids are unique to the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary "Weed".

In other CBD & Medical Marijuana news from the Cannabis sector:  GW Pharmaceuticals (NASDAQ: GWPH), a drug company that specializes in cannabis-based pharmaceuticals, was issued a Notice of Allowance from the U.S. Patent Office back in late 2013 for a patent application involving the use of THC and CBD, the two main chemicals in marijuana, for treating gliomas.  "The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume."  Read the full article at http://www.leafscience.com/2013/12/13/drug-maker-will-soon-hold-patent-thc-cbd-cancer-cures/

Insys Therapeutics, Inc. (NASDAQ: INSY) recently announced progress and expected milestones for multiple projects in its pipeline of innovative supportive care and therapy products and candidates. The Company intends to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) and to advance five programs into Phase III clinical trials in 2015.  "We have expanded our research and developments efforts while remaining focused on our two core areas of concentrations, the pharmaceutical cannabinoid space and sublingual sprays," said Michael L. Babich, President and Chief Executive Officer. "We have made strong progress in advancing our portfolio of product candidates, each of which aligns with our goal of commercializing innovative pharmaceuticals that will provide pain relief and other benefits to patients."

CannaVest Corp. (OTCQB: CANV), a leading manufacturer and distributor of hemp and Cannabidiol (CBD) based products, recently announced that the results of independent testing have proved the safety and quality of its products.  In December, CannaVest Corp. commenced cooperative efforts with Project CBD to ensure the cannabis/hemp industry and the consuming public is provided with accurate and meaningful information concerning CannaVest Corp.'s CBD offerings. Project CBD is a non-profit educational service dedicated to promoting and publicizing research into the medical utility of cannabidiol (CBD).  CannaVest Corp. initiated its cooperative efforts with Project CBD in response to a special report on the hemp oil industry published by Project CBD titled "Hemp Oil Hustlers" on October 14, 2014 and revised on November 5, 2014.  Project CBD reported that a consumer product, which is labeled as containing hemp oil and which was produced by the company and then sold in 2013 to a distributor, tested positive for hexane and other solvent residues.

Digital Brand Media & Marketing Group, Inc. (DBMM) continues to effect its Stage One strategy of advancing aggressive organic growth, following its retention by American Green, Inc. (OTCQB: ERBB) 2 months ago by jointly announcing the expansion of their contract to include a revenue share provision. The resultant contract was signed today. Both companies are advantaged by very positive market conditions in the digital marketing and marijuana industries, respectively.  Reggie James, Co-Chief Operating Officer and Senior Vice-President Marketing & Communications said, "There has been considerable interest by brands seeking to associate themselves in the evolving marijuana business, augmented by numerous examples of an influx of institutional capital, beyond wealthy individuals and family offices, which were early sources of funding. In 23 US-States it is now legal to use marijuana for medical purposes. Seeing the opportunity, serious, well known venture capital and private equity firms are taking significant positions in a variety of companies in North America."

In other OTC pain treatment news and happenings in the market place:  Tylenol® (acetaminophen), trademark of McNeil company, subsdiary of Johnson & Johnson (NYSE: JNJ) and Advil® (ibuprofen) trademark of Pfizer, Inc. (NYSE: PFE) are two more popular over-the-counter remedies to treat headaches, backache, fever, sore throats and more.  Review this latest analysis by Cleveland Clinic to determine which go-to medicine may be the right choice:  http://health.clevelandclinic.org/2013/09/acetaminophen-vs-ibuprofen-which-works-better/

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter:

http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by Stevia Corp by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: [email protected]
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.